Table 1. Ocriplasmin in clinical practice: patients achieving vitreomacular adhesion resolution.
| Institute | Patients | FTMH present | FTMH absent | ERM present | ERM absent | VMA ≤1500 μm | VMA >1500 μm |
|---|---|---|---|---|---|---|---|
| Bascom Palmer Eye Institute28 | 19 | 4/6 (66.7%) | 4/13 (30.8%) | 2/8 (50.0%) | 5/11 (45.0%) | 8/16 (50.0%) | 0/3 (0) |
| NJ Retina and Vitreous Centre29 | 52 | 11/15 (73.3%) | 7/37 (19.0%) | 1/11 (9.0%) | 17/41 (41/5%) | NR (38.0%)a | NR (0)b |
| California Retina Research Foundation30 | 25 | 8/11 (72.7%) | 6/14 (42.9%) | 13/23 (56.5%) | 1/2 (50.0%) | NA | NA |
| Cole Eye Institute31 | 17 | 2/2c (100.0%) | 6/14 (42.9%) | 1/3 (33.3%) | 7/14 (50.0%) | 8/13 (61.5%) | 0/4 (0) |
Abbreviations: ERM, epiretinal membrane; FTMH, full-thickness macular hole; VMA, vitreoretinal adhesion; NA, not applicable; NR, not reported.
a
VMA ≤750 μm.
b
VMA >751 μm.
c
Includes Stage 2 macular holes only, as per licenced indication for ocriplasmin.26